patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_230429 | REC_0017601 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 15.8 | 73 | female | 1 | 20 | 2.7 | 6 | sotorasib 960 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:36:02.466272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321660 | REC_0017602 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 13.9 | 76 | female | 1 | 13 | 5 | 4 | osimertinib 80 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:36:02.467075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356548 | REC_0017603 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 18.3 | 84 | female | 1 | 13 | 4.9 | 5 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:36:02.470287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828793 | REC_0017604 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 9.9 | 71 | female | 3 | 19 | 6.4 | 4 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:36:02.471152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275684 | REC_0017605 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 10.7 | 74 | female | 2 | 10 | 5.3 | 2 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:36:02.474118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287131 | REC_0017606 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8.1 | 70 | female | 2 | 20 | 3.6 | 8 | entrectinib 600 mg daily | 15.8 | true | MSS | 2026-03-15T05:36:02.475311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_151219 | REC_0017607 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 16.1 | 69 | female | 1 | 11 | 3.5 | 7 | pembrolizumab 200 mg q3w | 20.1 | false | MSS | 2026-03-15T05:36:02.476340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_816593 | REC_0017608 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 8.8 | 74 | male | 1 | 71 | 8.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.9 | true | MSS | 2026-03-15T05:36:02.477174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705755 | REC_0017609 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 10.1 | 72 | female | 1 | 81 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.5 | true | MSS | 2026-03-15T05:36:02.478032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445221 | REC_0017610 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 5.9 | 64 | female | 1 | 36 | 4.9 | 7 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:36:02.478895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114906 | REC_0017611 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.8 | 73 | male | 2 | 15 | 3.2 | 7 | alectinib 600 mg BID | 6.5 | true | MSI-H | 2026-03-15T05:36:02.479787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760928 | REC_0017612 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 8.8 | 69 | female | 0 | 23 | 5.4 | 5 | alectinib 600 mg BID | 14.9 | false | MSS | 2026-03-15T05:36:02.482959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833151 | REC_0017613 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.3 | 81 | female | 3 | 21 | 3.8 | 2 | osimertinib 80 mg daily | 22.1 | true | MSS | 2026-03-15T05:36:02.486478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960455 | REC_0017614 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 9 | 63 | female | 0 | 32 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.3 | false | MSS | 2026-03-15T05:36:02.487594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711834 | REC_0017615 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.9 | 54 | male | 0 | 12 | 8.9 | 10 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:36:02.490440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796168 | REC_0017616 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 1.6 | 62 | male | 1 | 30 | 7.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.7 | true | MSS | 2026-03-15T05:36:02.491891+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534477 | REC_0017617 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 22 | 3.2 | 73 | female | 1 | 61 | 4.9 | 0 | carboplatin + paclitaxel + pembrolizumab | 28.5 | true | MSS | 2026-03-15T05:36:02.493060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366880 | REC_0017618 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 15 | 83 | female | 2 | 14 | 6.9 | 4 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.493978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_735330 | REC_0017619 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.3 | 63 | male | 1 | 60 | 4.2 | 2 | pembrolizumab 200 mg q3w | 17.9 | true | MSS | 2026-03-15T05:36:02.494825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216997 | REC_0017620 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 34 | 17.8 | 65 | male | 0 | 16 | 5.5 | 1 | entrectinib 600 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:02.495724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809721 | REC_0017621 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 10.4 | 54 | female | 0 | 9 | 4.5 | 0 | osimertinib 80 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:36:02.496726+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445152 | REC_0017622 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.7 | 71 | female | 1 | 19 | 4.7 | 2 | entrectinib 600 mg daily | 16.1 | false | MSS | 2026-03-15T05:36:02.497569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755757 | REC_0017623 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 14.1 | 69 | female | 1 | 21 | 5.7 | 7 | entrectinib 600 mg daily | 17.9 | true | MSS | 2026-03-15T05:36:02.498404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730794 | REC_0017624 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 18.7 | 63 | female | 0 | 16 | 6.8 | 2 | sotorasib 960 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:36:02.499324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_611041 | REC_0017625 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.2 | 49 | male | 0 | 12 | 7.5 | 4 | sotorasib 960 mg daily | 10 | false | MSS | 2026-03-15T05:36:02.500813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_485912 | REC_0017626 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 11.5 | 66 | female | 1 | 7 | 4.6 | 2 | alectinib 600 mg BID | 19.6 | false | MSS | 2026-03-15T05:36:02.501765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967357 | REC_0017627 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 12.9 | 74 | male | 2 | 14 | 6.7 | 1 | entrectinib 600 mg daily | 23.5 | false | MSI-H | 2026-03-15T05:36:02.502840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371155 | REC_0017628 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 37 | 12.1 | 57 | female | 0 | 18 | 6.4 | 5 | alectinib 600 mg BID | 13.5 | false | MSI-H | 2026-03-15T05:36:02.504444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196862 | REC_0017629 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.8 | 58 | male | 1 | 11 | 6.8 | 5 | sotorasib 960 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:36:02.505616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573976 | REC_0017630 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 38 | 3.1 | 71 | male | 1 | 71 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:36:02.506466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633572 | REC_0017631 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 4.4 | 70 | female | 2 | 16 | 4.9 | 2 | osimertinib 80 mg daily | 15.3 | true | MSS | 2026-03-15T05:36:02.507403+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395447 | REC_0017632 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 16.2 | 69 | male | 0 | 6 | 4.7 | 2 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:36:02.509442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153185 | REC_0017633 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 16.5 | 77 | female | 1 | 17 | 6 | 1 | alectinib 600 mg BID | 18.1 | false | MSS | 2026-03-15T05:36:02.510731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881529 | REC_0017634 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 12.8 | 50 | female | 0 | 19 | 4.5 | 1 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:36:02.511535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463415 | REC_0017635 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 6.7 | 67 | female | 1 | 45 | 6.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 46.5 | false | MSS | 2026-03-15T05:36:02.512491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345714 | REC_0017636 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 9.6 | 61 | female | 0 | 18 | 3.3 | 2 | alectinib 600 mg BID | 20.7 | false | MSS | 2026-03-15T05:36:02.513555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297999 | REC_0017637 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7.8 | 72 | female | 0 | 57 | 6 | 3 | carboplatin + paclitaxel + pembrolizumab | 26.5 | true | MSS | 2026-03-15T05:36:02.514450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458673 | REC_0017638 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 9.7 | 65 | male | 1 | 12 | 3.1 | 1 | osimertinib 80 mg daily | 21.1 | false | MSS | 2026-03-15T05:36:02.515245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740497 | REC_0017639 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 9 | 66 | female | 1 | 21 | 7.4 | 2 | osimertinib 80 mg daily | 21.4 | false | MSS | 2026-03-15T05:36:02.515992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451871 | REC_0017640 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.5 | 66 | female | 1 | 19 | 3.9 | 2 | pembrolizumab 200 mg q3w | 19.1 | true | MSS | 2026-03-15T05:36:02.517428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105713 | REC_0017641 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.1 | 65 | female | 1 | 14 | 4.2 | 2 | entrectinib 600 mg daily | 35.1 | false | MSS | 2026-03-15T05:36:02.518116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454746 | REC_0017642 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.9 | 71 | female | 2 | 0 | 5.4 | 1 | sotorasib 960 mg daily | 17.4 | false | MSS | 2026-03-15T05:36:02.519333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_602210 | REC_0017643 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.3 | 78 | male | 1 | 11 | 6.2 | 6 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:36:02.520963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700434 | REC_0017644 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 6.6 | 62 | female | 1 | 7 | 5.4 | 6 | sotorasib 960 mg daily | 4.8 | true | MSS | 2026-03-15T05:36:02.521845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262475 | REC_0017645 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.3 | 64 | male | 0 | 41 | 4.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.3 | false | MSS | 2026-03-15T05:36:02.522567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_943464 | REC_0017646 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 35 | 6 | 80 | male | 2 | 57 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.7 | true | MSS | 2026-03-15T05:36:02.523283+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315439 | REC_0017647 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 13.7 | 63 | female | 1 | 13 | 4.8 | 2 | alectinib 600 mg BID | 17.5 | true | MSI-H | 2026-03-15T05:36:02.524624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892998 | REC_0017648 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 15.7 | 56 | female | 1 | 10 | 5.8 | 4 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:02.525490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242234 | REC_0017649 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 7.4 | 59 | female | 1 | 13 | 6 | 1 | sotorasib 960 mg daily | 16.8 | false | MSS | 2026-03-15T05:36:02.526354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978527 | REC_0017650 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 8.7 | 71 | male | 3 | 17 | 4.1 | 6 | alectinib 600 mg BID | 11.2 | true | MSS | 2026-03-15T05:36:02.527123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991719 | REC_0017651 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 5.1 | 67 | male | 1 | 36 | 5.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSS | 2026-03-15T05:36:02.527864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_724935 | REC_0017652 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 6.1 | 83 | female | 2 | 17 | 7.2 | 4 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:36:02.528900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382114 | REC_0017653 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 10.3 | 76 | female | 2 | 15 | 7.1 | 1 | sotorasib 960 mg daily | 18.9 | false | MSS | 2026-03-15T05:36:02.529855+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647955 | REC_0017654 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 8.2 | 74 | male | 3 | 12 | 6 | 5 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:02.532832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123394 | REC_0017655 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 15 | 70 | male | 2 | 7 | 5 | 4 | osimertinib 80 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:02.534216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_867599 | REC_0017656 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 10.1 | 74 | female | 1 | 15 | 4.7 | 1 | entrectinib 600 mg daily | 18.6 | false | MSI-H | 2026-03-15T05:36:02.534989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409759 | REC_0017657 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 13.5 | 72 | female | 1 | 19 | 4.4 | 5 | entrectinib 600 mg daily | 18 | true | MSI-H | 2026-03-15T05:36:02.535702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337356 | REC_0017658 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 18.7 | 63 | female | 1 | 23 | 3.9 | 0 | osimertinib 80 mg daily | 22.4 | false | MSS | 2026-03-15T05:36:02.536615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875489 | REC_0017659 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.7 | 75 | male | 2 | 11 | 5.2 | 4 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:02.540351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956319 | REC_0017660 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.4 | 72 | female | 0 | 72 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.4 | false | MSS | 2026-03-15T05:36:02.541179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588321 | REC_0017661 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 12 | 17.5 | 58 | female | 0 | 18 | 4.6 | 2 | osimertinib 80 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:36:02.541969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888483 | REC_0017662 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10.3 | 67 | female | 1 | 19 | 3.3 | 1 | sotorasib 960 mg daily | 26.7 | false | MSS | 2026-03-15T05:36:02.543779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755890 | REC_0017663 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 5 | 67 | female | 0 | 56 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.2 | true | MSS | 2026-03-15T05:36:02.544727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455394 | REC_0017664 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 2.8 | 61 | female | 1 | 13 | 7.1 | 3 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:36:02.545526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_775107 | REC_0017665 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 8.4 | 62 | male | 0 | 20 | 5.4 | 2 | alectinib 600 mg BID | 6.4 | true | MSS | 2026-03-15T05:36:02.546407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350990 | REC_0017666 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 3.6 | 72 | male | 1 | 45 | 6.7 | 6 | pembrolizumab 200 mg q3w | 11.7 | false | MSS | 2026-03-15T05:36:02.547975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_295343 | REC_0017667 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.2 | 69 | female | 0 | 21 | 6 | 5 | entrectinib 600 mg daily | 8.9 | true | MSI-H | 2026-03-15T05:36:02.549287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260695 | REC_0017668 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5.8 | 59 | female | 1 | 33 | 4.4 | 6 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:36:02.550469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207872 | REC_0017669 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 9.6 | 59 | male | 1 | 9 | 6.4 | 2 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:36:02.551879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343446 | REC_0017670 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 9.5 | 63 | female | 0 | 7 | 6.1 | 1 | entrectinib 600 mg daily | 19.5 | false | MSS | 2026-03-15T05:36:02.552803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859744 | REC_0017671 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 11.1 | 51 | female | 0 | 5 | 7.7 | 1 | entrectinib 600 mg daily | 17.2 | false | MSI-H | 2026-03-15T05:36:02.553615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_398734 | REC_0017672 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 15.2 | 64 | female | 1 | 10 | 6.6 | 2 | sotorasib 960 mg daily | 9.2 | false | MSI-H | 2026-03-15T05:36:02.554536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981350 | REC_0017673 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.6 | 64 | male | 1 | 16 | 5.4 | 4 | sotorasib 960 mg daily | 6 | true | MSI-H | 2026-03-15T05:36:02.555387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638798 | REC_0017674 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 7.3 | 58 | female | 0 | 8 | 4 | 1 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:02.556233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652437 | REC_0017675 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.8 | 54 | male | 0 | 11 | 4.5 | 5 | osimertinib 80 mg daily | 21.5 | true | MSS | 2026-03-15T05:36:02.556988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545754 | REC_0017676 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 8.5 | 52 | female | 0 | 15 | 7.3 | 1 | osimertinib 80 mg daily | 25.4 | true | MSS | 2026-03-15T05:36:02.557883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668456 | REC_0017677 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 6 | 90 | female | 2 | 22 | 4.7 | 2 | sotorasib 960 mg daily | 22.2 | true | MSS | 2026-03-15T05:36:02.558735+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747906 | REC_0017678 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 18 | 14.1 | 69 | male | 0 | 20 | 4 | 0 | sotorasib 960 mg daily | 46.9 | false | MSS | 2026-03-15T05:36:02.559723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794577 | REC_0017679 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 25 | 15.9 | 49 | male | 0 | 13 | 5.7 | 0 | alectinib 600 mg BID | 52.5 | true | MSI-H | 2026-03-15T05:36:02.561319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791183 | REC_0017680 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 9.9 | 80 | female | 2 | 11 | 3 | 2 | pembrolizumab 200 mg q3w | 19 | false | MSS | 2026-03-15T05:36:02.562257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612597 | REC_0017681 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 26 | 13.4 | 64 | female | 0 | 15 | 8.2 | 0 | osimertinib 80 mg daily | 22.5 | false | MSI-H | 2026-03-15T05:36:02.563612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141850 | REC_0017682 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 8 | 5.6 | 72 | female | 2 | 50 | 7.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:36:02.564548+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589252 | REC_0017683 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.6 | 61 | female | 0 | 24 | 5.2 | 6 | entrectinib 600 mg daily | 8.8 | false | MSS | 2026-03-15T05:36:02.565413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804267 | REC_0017684 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.5 | 62 | male | 1 | 17 | 5.5 | 4 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:36:02.566261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843920 | REC_0017685 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 11.3 | 72 | female | 1 | 18 | 6.1 | 5 | entrectinib 600 mg daily | 8.7 | true | MSS | 2026-03-15T05:36:02.567133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422904 | REC_0017686 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.2 | 67 | female | 1 | 0 | 6.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:36:02.568017+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_363775 | REC_0017687 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 2.4 | 62 | male | 0 | 53 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:36:02.568977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140288 | REC_0017688 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 9.4 | 71 | female | 2 | 21 | 7.3 | 5 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:36:02.571389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243651 | REC_0017689 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.4 | 60 | male | 0 | 31 | 4.5 | 3 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:36:02.572331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323048 | REC_0017690 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 14.2 | 67 | female | 1 | 6 | 6.2 | 1 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:02.574437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992371 | REC_0017691 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.8 | 79 | female | 2 | 13 | 5.9 | 2 | osimertinib 80 mg daily | 28.9 | false | MSS | 2026-03-15T05:36:02.575349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977502 | REC_0017692 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 19.5 | 64 | male | 1 | 7 | 6.3 | 1 | osimertinib 80 mg daily | 17.8 | true | MSS | 2026-03-15T05:36:02.576321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714068 | REC_0017693 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 7.4 | 75 | female | 2 | 31 | 3.3 | 2 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:36:02.577197+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_590685 | REC_0017694 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9.2 | 65 | female | 1 | 22 | 3.6 | 6 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:36:02.578392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208059 | REC_0017695 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 26 | 5.3 | 71 | female | 1 | 51 | 5.5 | 0 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:36:02.579237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_581558 | REC_0017696 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7 | 77 | female | 3 | 26 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.2 | true | MSS | 2026-03-15T05:36:02.580309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958247 | REC_0017697 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 7.7 | 64 | male | 1 | 16 | 4.7 | 6 | sotorasib 960 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:02.581268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101532 | REC_0017698 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8 | 80 | female | 1 | 9 | 6.5 | 6 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:36:02.582170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312029 | REC_0017699 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 15.7 | 73 | female | 3 | 10 | 4.1 | 6 | entrectinib 600 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:36:02.582997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841881 | REC_0017700 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 8.5 | 60 | female | 1 | 14 | 4.2 | 6 | sotorasib 960 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:02.583863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.